南华生物
(000504)
| 流通市值：31.56亿 | | | 总市值：33.53亿 |
| 流通股本：3.11亿 | | | 总股本：3.30亿 |
| 报告期 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 流动资产: | | | | |
| 货币资金 | 214,737,973.7 | 204,539,871.63 | 212,627,686.65 | 493,811,075.4 |
| 应收票据及应收账款 | 129,217,053.18 | 124,635,074.26 | 124,167,490.38 | 123,224,428.84 |
| 应收账款 | 129,217,053.18 | 124,635,074.26 | 124,167,490.38 | 123,224,428.84 |
| 预付款项 | 8,573,224.1 | 3,385,717.94 | 6,774,819.28 | 3,615,590.39 |
| 其他应收款合计 | 11,822,002.54 | 10,873,806.85 | 16,068,464.56 | 14,592,307.68 |
| 存货 | 19,581,307.29 | 18,443,831.52 | 14,212,949.89 | 10,660,296.88 |
| 其他流动资产 | 8,417,922.01 | 7,886,082.11 | 23,453,184.31 | 7,229,117.81 |
| 流动资产平衡项目 | 0 | 0 | 0 | 0 |
| 流动资产合计 | 492,882,061.82 | 472,210,483.31 | 497,830,396.07 | 654,851,149.02 |
| 非流动资产: | | | | |
| 长期股权投资 | - | 2,692,448.15 | 5,415,798.33 | 5,415,798.33 |
| 固定资产 | 13,505,078.63 | 13,966,797.06 | 14,107,948.11 | 14,281,834.43 |
| 使用权资产 | 11,535,254.09 | 11,830,998.76 | 13,046,706.71 | 13,778,304.35 |
| 无形资产 | 398,439.72 | 412,565.49 | 426,691.26 | 440,817.03 |
| 商誉 | 1,983,226.77 | 1,983,226.77 | 1,983,226.77 | 1,983,226.77 |
| 长期待摊费用 | 72,334,986.34 | 75,018,642.11 | 77,344,300.68 | 79,483,679.17 |
| 递延所得税资产 | 1,410,011.39 | 1,410,011.39 | 1,109,736.86 | 1,109,736.86 |
| 其他非流动资产 | 37,970.13 | 37,970.13 | 37,970.13 | 37,970.13 |
| 非流动资产平衡项目 | 0 | 0 | 0 | 0 |
| 非流动资产合计 | 101,204,967.07 | 107,352,659.86 | 113,472,378.85 | 116,531,367.07 |
| 资产平衡项目 | 0 | 0 | 0 | 0 |
| 资产总计 | 594,087,028.89 | 579,563,143.17 | 611,302,774.92 | 771,382,516.09 |
| 流动负债: | | | | |
| 短期借款 | - | - | 28,111,125.04 | 28,116,544.47 |
| 应付票据及应付账款 | 70,562,975.46 | 80,413,693.87 | 79,461,114.15 | 82,212,590.57 |
| 应付账款 | 70,562,975.46 | 80,413,693.87 | 79,461,114.15 | 82,212,590.57 |
| 合同负债 | 174,526,437.7 | 169,508,453.65 | 162,411,469.26 | 151,410,103.83 |
| 应付职工薪酬 | 3,260,040.23 | 3,151,222.14 | 3,701,976.83 | 7,129,353.85 |
| 应交税费 | 2,239,258.1 | 1,235,935.38 | 295,510.21 | 2,849,119.13 |
| 其他应付款合计 | 4,277,242.43 | 4,381,493.73 | 6,687,049.16 | 166,024,258.76 |
| 应付股利 | 931,102.81 | 931,102.81 | 931,102.81 | 931,102.81 |
| 一年内到期的非流动负债 | 1,494,132.48 | 3,326,360.43 | 332,263.09 | 3,157,895.03 |
| 其他流动负债 | 12,752,434.73 | 12,520,495.61 | 13,376,791.75 | 11,496,805.61 |
| 流动负债平衡项目 | 0 | 0 | 0 | 0 |
| 流动负债合计 | 269,112,521.13 | 274,537,654.81 | 294,377,299.49 | 452,396,671.25 |
| 非流动负债: | | | | |
| 长期借款 | 9,000,000 | - | - | - |
| 租赁负债 | 13,920,288.64 | 10,897,797.21 | 13,858,840.48 | 13,002,574.72 |
| 递延收益 | 681,732 | 1,137,245 | 1,016,158 | 1,058,871 |
| 递延所得税负债 | 168,396.3 | 195,750.27 | 223,140.56 | 250,530.86 |
| 非流动负债平衡项目 | 0 | 0 | 0 | 0 |
| 非流动负债合计 | 23,770,416.94 | 12,230,792.48 | 15,098,139.04 | 14,311,976.58 |
| 负债平衡项目 | 0 | 0 | 0 | 0 |
| 负债合计 | 292,882,938.07 | 286,768,447.29 | 309,475,438.53 | 466,708,647.83 |
| 所有者权益(或股东权益): | | | | |
| 实收资本(或股本) | 330,023,098 | 330,023,098 | 330,023,098 | 330,023,098 |
| 资本公积 | 430,981,998.93 | 423,472,870.01 | 423,472,870.01 | 423,472,870.01 |
| 盈余公积 | 34,545,734.18 | 34,545,734.18 | 34,545,734.18 | 34,545,734.18 |
| 未分配利润 | -546,903,703.31 | -539,493,334.1 | -533,871,157.35 | -531,100,503.82 |
| 归属于母公司股东权益平衡项目 | 0 | 0 | 0 | 0 |
| 归属于母公司股东权益合计 | 248,647,127.8 | 248,548,368.09 | 254,170,544.84 | 256,941,198.37 |
| 少数股东权益 | 52,556,963.02 | 44,246,327.79 | 47,656,791.55 | 47,732,669.89 |
| 股东权益平衡项目 | 0 | 0 | 0 | 0 |
| 股东权益合计 | 301,204,090.82 | 292,794,695.88 | 301,827,336.39 | 304,673,868.26 |
| 负债和股东权益合计 | 594,087,028.89 | 579,563,143.17 | 611,302,774.92 | 771,382,516.09 |
| 公告日期 | 2024-10-31 | 2024-08-31 | 2024-04-30 | 2024-04-30 |
| 审计意见(境内) | | | | 标准无保留意见 |